AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19620163 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study 17401684 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent scatter-site apartments with the Housing First approach
Number of subjects: 0
Study 17401684 — intervention group
Group type: COMPARATOR
Intervention: Services as usual
Number of subjects: 0
Study 15453911 — intervention group
Group type: EXPERIMENTAL
Intervention: Email reminders (up to 33 contacts over 45 weeks)
Number of subjects: 445
Study 15453911 — intervention group
Group type: EXPERIMENTAL
Intervention: Email reminders (first 10 emails)
Number of subjects: 445
Study 15453911 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline screening rates
Number of subjects: 445
Study 15453911 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of email reminders
Number of subjects: 445
Study 11554430 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopegyt tablets (250 mg alpha-methyldopa)
Number of subjects: 24
Study 11554430 — intervention group
Group type: COMPARATOR
Intervention: Presinol film tablets (250 mg alpha-methyldopa)
Number of subjects: 24
Study 11554430 — intervention group
Group type: COMPARATOR
Intervention: Dopegyt solution (250 mg/50 ml)
Number of subjects: 24
Study 9350912 — intervention group
Group type: EXPERIMENTAL
Intervention: Anistreplase (30 U) given intravenously before hospital admission (prehospital treatment group)
Number of subjects: 311
Study 9350912 — intervention group
Group type: COMPARATOR
Intervention: Anistreplase (30 U) given intravenously in the hospital (hospital treatment group)
Number of subjects: 311
Study 9350912 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay in thrombolytic treatment by 1 hour
Number of subjects: 311
Study 9350912 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay in thrombolytic treatment by 30 minutes
Number of subjects: 311
Study 1375019 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 21
Study 1375019 — intervention group
Group type: COMPARATOR
Intervention: Fluphenazine
Number of subjects: 21
Study 1375019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 4012967 — intervention group
Group type: EXPERIMENTAL
Intervention: mezlocillin
Number of subjects: 100
Study 4012967 — intervention group
Group type: COMPARATOR
Intervention: cefotaxime
Number of subjects: 100
Study 31145794 — intervention group
Group type: EXPERIMENTAL
Intervention: AtHSFA7b
Number of subjects: 0
Study 29471518 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive music and imagery
Number of subjects: 0
Study 29471518 — intervention group
Group type: COMPARATOR
Intervention: Preferred music listening
Number of subjects: 0
Study 27747394 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice to walk for 10 min after each main meal
Number of subjects: 41
Study 27747394 — intervention group
Group type: COMPARATOR
Intervention: Advice to walk 30 min each day
Number of subjects: 41
Study 25297058 — intervention group
Group type: EXPERIMENTAL
Intervention: Y-75 (6 g/day)
Number of subjects: 72
Study 25297058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 23559666 — intervention group
Group type: EXPERIMENTAL
Intervention: On-field supervised group
Number of subjects: 226
Study 23559666 — intervention group
Group type: EXPERIMENTAL
Intervention: High adherence to the FIFA 11+
Number of subjects: 226
Study 23559666 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised group
Number of subjects: 226
Study 20944041 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical permethrin (5% cream)
Number of subjects: 0
Study 20944041 — intervention group
Group type: COMPARATOR
Intervention: 7% sulfur preparation
Number of subjects: 0
Study 17440522 — intervention group
Group type: EXPERIMENTAL
Intervention: High glycaemic index (HGI) evening meal
Number of subjects: 7
Study 17440522 — intervention group
Group type: COMPARATOR
Intervention: Low glycaemic index (LGI) evening meal
Number of subjects: 7
Study 16837436 — intervention group
Group type: EXPERIMENTAL
Intervention: NZGLM oil preparation (2 mL/day)
Number of subjects: 30
Study 16837436 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil preparation (2 mL/day)
Number of subjects: 30
Study 16837436 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 30
Study 14551837 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom made anatomic femoral stems
Number of subjects: 31
Study 14551837 — intervention group
Group type: COMPARATOR
Intervention: Standard straight femoral stems
Number of subjects: 31
Study 11310810 — intervention group
Group type: EXPERIMENTAL
Intervention: Women who called the research line to quit smoking (intervention group)
Number of subjects: 4000
Study 8643226 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietician counseling aimed at weight maintenance
Number of subjects: 107
Study 8643226 — intervention group
Group type: COMPARATOR
Intervention: Control group (no formalized dietician counseling)
Number of subjects: 107
Study 1614462 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (500 mg per kilogram of body weight per day)
Number of subjects: 588
Study 1614462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 588
Study 1614462 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin
Number of subjects: 588
Study 6998552 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine, 0.05 mg twice daily
Number of subjects: 66
Study 6998552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 30954330 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropattern oriented exploratory treatment (intervention group, IG)
Number of subjects: 178
Study 30954330 — intervention group
Group type: COMPARATOR
Intervention: Standard care (treatment as usual, standard group, SG)
Number of subjects: 178
Study 28416827 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Anterior Approach (DAA)
Number of subjects: 82
Study 28416827 — intervention group
Group type: COMPARATOR
Intervention: Posterolateral Piriformis-sparing Approach (Mis-PLA)
Number of subjects: 82
Study 26011509 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG and optimal medical therapy (MED)
Number of subjects: 1212
Study 26011509 — intervention group
Group type: COMPARATOR
Intervention: MED alone
Number of subjects: 1212
Study 23803797 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychic Representation focused Psychotherapy (PRFP) - 20 sessions
Number of subjects: 53
Study 23803797 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (Control group) - 26 patients
Number of subjects: 53
Study 21860046 — intervention group
Group type: EXPERIMENTAL
Intervention: Social cognition
Number of subjects: 148
Study 21860046 — intervention group
Group type: EXPERIMENTAL
Intervention: Social cognition and other variables (motivation, social competence)
Number of subjects: 148
Study 19347726 — intervention group
Group type: EXPERIMENTAL
Intervention: XM02 (5 microg/kg/day, subcutaneous, for at least 5 days and a maximum of 14 days)
Number of subjects: 92
Study 19347726 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim (5 microg/kg/day, subcutaneous, for at least 5 days and a maximum of 14 days)
Number of subjects: 92
Study 19347726 — intervention group
Group type: EXPERIMENTAL
Intervention: XM02
Number of subjects: 92
Study 19347726 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim
Number of subjects: 92
Study 17721960 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissociation induction via audiophotic stimulation
Number of subjects: 120
Study 17721960 — intervention group
Group type: COMPARATOR
Intervention: Credible control condition
Number of subjects: 120
Study 17036619 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise alone
Number of subjects: 1092
Study 17036619 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and cognitive-behavioral therapy
Number of subjects: 1092
Study 12707157 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 15 micro g with bupivacaine 6 mg
Number of subjects: 45
Study 12707157 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 30 micro g with bupivacaine 6 mg
Number of subjects: 45
Study 12707157 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 6 mg with saline (Control Group B)
Number of subjects: 45
Study 10626094 — intervention group
Group type: EXPERIMENTAL
Intervention: Lazabemide
Number of subjects: 51
Study 10626094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 8574749 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 5 mg/kg intravenous infusion over 180 min
Number of subjects: 23
Study 8574749 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (Control)
Number of subjects: 23
Study 2077492 — intervention group
Group type: EXPERIMENTAL
Intervention: Autopolymerized Delton fissure sealants
Number of subjects: 73
Study 2077492 — intervention group
Group type: COMPARATOR
Intervention: Light-polymerized Delton fissure sealants
Number of subjects: 73
Study 6452297 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical erythromycin (1%) in a new penetrative vehicle
Number of subjects: 28
Study 6452297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 31628271 — intervention group
Group type: EXPERIMENTAL
Intervention: Early controlled aerobic exercise
Number of subjects: 0
Study 31628271 — intervention group
Group type: COMPARATOR
Intervention: Usual care or delayed exercise
Number of subjects: 0
Study 26768873 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscope-assisted keyhole technique
Number of subjects: 184
Study 26768873 — intervention group
Group type: COMPARATOR
Intervention: Traditional craniotomy
Number of subjects: 184
Study 25669083 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercostal analgesia (ICA) with 2 ml x hr(‐1) of 0.2% ropivacaine and intravenous fentanyl (0.25 x μg(‐1). kg(‐1) x hr(‐1))
Number of subjects: 22
Study 25669083 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia with 2 ml x hr(‐1) of 0.2% ropivacaine and intravenous fentanyl (0.25 x μg(‐1). kg(‐1) x hr(‐1))
Number of subjects: 22
Study 23368423 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse case management (NCM) with motivational interviewing (MI)
Number of subjects: 545
Study 23368423 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 545
Study 20417488 — intervention group
Group type: EXPERIMENTAL
Intervention: IL1beta‐511 minor allele
Number of subjects: 272
Study 20417488 — intervention group
Group type: EXPERIMENTAL
Intervention: IL6‐176 minor allele
Number of subjects: 272
Study 20417488 — intervention group
Group type: EXPERIMENTAL
Intervention: IL4R‐148 minor allele
Number of subjects: 272
Study 19001265 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralymphatic allergen administration (3 injections over 2 months, cumulative allergen dose 3,000 SQ-U)
Number of subjects: 165
Study 19001265 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralymphatic allergen administration
Number of subjects: 165
Study 19001265 — intervention group
Group type: COMPARATOR
Intervention: s.c. immunotherapy (54 injections over 3 years, cumulative allergen dose 4,031,540 SQ-U)
Number of subjects: 165
Study 16280777 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CyA) 1.5 mg/kg twice daily
Number of subjects: 64
Study 16280777 — intervention group
Group type: COMPARATOR
Intervention: Pentosan polysulfate sodium (PPS) 100 mg 3 times daily
Number of subjects: 64
Study 12182757 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of intravenous erythromycin
Number of subjects: 20
Study 12182757 — intervention group
Group type: COMPARATOR
Intervention: 4 mg of intravenous ondansetron (10 subjects)
Number of subjects: 20
Study 12182757 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micro g octreotide
Number of subjects: 20
Study 12182757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10645353 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular lignocaine (IAL)
Number of subjects: 0
Study 10645353 — intervention group
Group type: COMPARATOR
Intervention: Entonox
Number of subjects: 0
Study 8523317 — intervention group
Group type: EXPERIMENTAL
Intervention: Nylon vertical mattress sutures
Number of subjects: 93
Study 8523317 — intervention group
Group type: COMPARATOR
Intervention: Interrupted subcuticular polydioxanone (PDS) sutures
Number of subjects: 93
Study 2027658 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer Orthoptics Diagnostic Program
Number of subjects: 40
Study 2027658 — intervention group
Group type: COMPARATOR
Intervention: Standard Lens Flipper Method
Number of subjects: 40
Study 7327728 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimon and Hughston osteotomy
Number of subjects: 150
Study 7327728 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarmiento osteotomy
Number of subjects: 150
Study 7327728 — intervention group
Group type: COMPARATOR
Intervention: Skeletal traction with a tibial pin
Number of subjects: 150
Study 31414269 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (0.5 mg/kg every 6 hours)
Number of subjects: 40
Study 31414269 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 40
Study 27312566 — intervention group
Group type: EXPERIMENTAL
Intervention: Watching TV for > 1 hour/day during weekdays
Number of subjects: 6431
Study 25835642 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol (600μg)
Number of subjects: 200
Study 25835642 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular oxytocin (1mL of 10IU)
Number of subjects: 200
Study 25835642 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Number of subjects: 200
Study 24237999 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept monotherapy
Number of subjects: 682
Study 24237999 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept with methotrexate
Number of subjects: 682
Study 21349938 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin 0.1% and ultraviolet A (370 nm at 3 mW/cm(2))
Number of subjects: 24
Study 19805689 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented therapy (intensive postinduction treatment)
Number of subjects: 262
Study 19805689 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 262
Study 17220608 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m2 x 4 weekly infusions)
Number of subjects: 90
Study 17220608 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (phase I study)
Number of subjects: 90
Study 15610331 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% weight loss
Number of subjects: 365
Study 15610331 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% weight loss
Number of subjects: 365
Study 15610331 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% weight loss
Number of subjects: 365
Study 15610331 — intervention group
Group type: EXPERIMENTAL
Intervention: Current weight
Number of subjects: 365
Study 15610331 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% weight loss among obese patients
Number of subjects: 365
Study 11061678 — intervention group
Group type: EXPERIMENTAL
Intervention: WeiniCom
Number of subjects: 42
Study 11061678 — intervention group
Group type: COMPARATOR
Intervention: buprenorphine
Number of subjects: 42
Study 9306142 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal subjects
Number of subjects: 19
Study 9306142 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with left ventricular aneurysm
Number of subjects: 19
Study 9306142 — intervention group
Group type: COMPARATOR
Intervention: Comparison between normal subjects and patients with LV aneurysm
Number of subjects: 19
Study 8326971 — intervention group
Group type: EXPERIMENTAL
Intervention: Anistreplase administered before admission (prehospital group)
Number of subjects: 5469
Study 8326971 — intervention group
Group type: COMPARATOR
Intervention: Anistreplase administered in the hospital (hospital group)
Number of subjects: 5469
Study 8326971 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital group
Number of subjects: 5469
Study 8326971 — intervention group
Group type: COMPARATOR
Intervention: Hospital group
Number of subjects: 5469
Study 3097691 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium with partial sleep deprivation (PSD)
Number of subjects: 0
Study 3097691 — intervention group
Group type: COMPARATOR
Intervention: Placebo with partial sleep deprivation (PSD)
Number of subjects: 0
Study 3097691 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium alone without PSD
Number of subjects: 0
Study 30572161 — intervention group
Group type: EXPERIMENTAL
Intervention: New salad bars
Number of subjects: 6804
Study 30572161 — intervention group
Group type: EXPERIMENTAL
Intervention: Salad bars with marketing intervention
Number of subjects: 6804
Study 30572161 — intervention group
Group type: EXPERIMENTAL
Intervention: Salad bars
Number of subjects: 6804
Study 30572161 — intervention group
Group type: COMPARATOR
Intervention: Traditional serving methods
Number of subjects: 6804
Study 30026128 — intervention group
Group type: EXPERIMENTAL
Intervention: WL + SitLess
Number of subjects: 180
Study 30026128 — intervention group
Group type: EXPERIMENTAL
Intervention: WL + EX
Number of subjects: 180
Study 30026128 — intervention group
Group type: EXPERIMENTAL
Intervention: WL + EX + SitLess
Number of subjects: 180
Study 27522312 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine 2 ml with dexmedetomidine 14 μg peripherally
Number of subjects: 90
Study 27522312 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine 2 ml only (control)
Number of subjects: 90
Study 27522312 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine 2 ml with dexmedetomidine 14 μg systemically
Number of subjects: 90
Study 24477514 — intervention group
Group type: EXPERIMENTAL
Intervention: MBSR(BC) intervention group
Number of subjects: 41
Study 24477514 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 41
Study 22710563 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led, community-based chronic disease self-management program
Number of subjects: 582
Study 22710563 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 582
Study 20695899 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental diet treatment
Number of subjects: 0
Study 18192787 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymerase chain reaction-based diagnostics
Number of subjects: 0
Study 18192787 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of T. vaginalis
Number of subjects: 0
Study 18192787 — intervention group
Group type: EXPERIMENTAL
Intervention: Control interventions for T. vaginalis
Number of subjects: 0
Study 15802410 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system
Number of subjects: 62
Study 15802410 — intervention group
Group type: COMPARATOR
Intervention: Copper T 380A intrauterine device
Number of subjects: 62
Study 12795730 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited intervention (provider educational session and examination room posters)
Number of subjects: 1518
Study 12795730 — intervention group
Group type: EXPERIMENTAL
Intervention: Full intervention (provider educational session, examination room posters, and completion of ICE module)
Number of subjects: 1518
Study 12795730 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited intervention
Number of subjects: 1518
Study 12795730 — intervention group
Group type: EXPERIMENTAL
Intervention: Full intervention
Number of subjects: 1518
Study 16676932 — intervention group
Group type: EXPERIMENTAL
Intervention: Syrinx decompression combined with spinal cord untethering
Number of subjects: 30
Study 16676932 — intervention group
Group type: COMPARATOR
Intervention: Spinal cord untethering alone
Number of subjects: 30
Study 8923069 — intervention group
Group type: EXPERIMENTAL
Intervention: Weaning protocol
Number of subjects: 101
Study 8923069 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 101
Study 1409461 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg + hydrochlorothiazide (HCTZ) 25 mg
Number of subjects: 42
Study 1409461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 4010387 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 X 75 mg pirlindol daily for two weeks
Number of subjects: 10
Study 4010387 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg pirlindol (single dose)
Number of subjects: 10
Study 4010387 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 X 75 mg pirlindol (after one week treatment)
Number of subjects: 10
Study 4010387 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 10
Study 4010387 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg and 225 mg pirlindol (superimposed dosage on days 8 and 15)
Number of subjects: 10
Study 4010387 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of blood pressure, pulse rate and side effects
Number of subjects: 10
Study 31424244 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-month YMCA gym membership plus a 16-week integrated motivational intervention for exercise (MI + CM)
Number of subjects: 66
Study 31424244 — intervention group
Group type: COMPARATOR
Intervention: 4-month YMCA gym membership only (MO)
Number of subjects: 66
Study 31424244 — intervention group
Group type: EXPERIMENTAL
Intervention: Both study conditions (MO and MI + CM)
Number of subjects: 66
Study 31298269 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 0
Study 31298269 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density lipoprotein cholesterol (HDL-C)
Number of subjects: 0
Study 27769697 — intervention group
Group type: EXPERIMENTAL
Intervention: Water Resistance Therapy (WRT)
Number of subjects: 20
Study 27769697 — intervention group
Group type: COMPARATOR
Intervention: Tube Phonation with the distal end in air (TPA)
Number of subjects: 20
Study 26052866 — intervention group
Group type: EXPERIMENTAL
Intervention: Darexaban 15 mg bid
Number of subjects: 1297
Study 26052866 — intervention group
Group type: EXPERIMENTAL
Intervention: Darexaban 30 mg qd
Number of subjects: 1297
Study 26052866 — intervention group
Group type: EXPERIMENTAL
Intervention: Darexaban 30 mg bid
Number of subjects: 1297
Study 26052866 — intervention group
Group type: EXPERIMENTAL
Intervention: Darexaban 60 mg qd
Number of subjects: 1297
Study 26052866 — intervention group
Group type: EXPERIMENTAL
Intervention: Darexaban 60 mg bid
Number of subjects: 1297
Study 26052866 — intervention group
Group type: EXPERIMENTAL
Intervention: Darexaban 120 mg qd
Number of subjects: 1297